Astrocyte Pharmaceuticals Inc. Raises $9.5M Series A+

Astrocyte Pharmaceuticals Inc. raises $9.5M Series A+ led by undisclosed investors.

Participants in this funding round include various institutional and private investors.

Astrocyte Pharmaceuticals develops cerebroprotective therapies for concussion, traumatic brain injury (TBI), and stroke. The company is led by CEO Jeffrey W. Kauffman.

Company	Astrocyte Pharmaceuticals Inc.
Round	Series A+
Amount	$9.5M
Sectors	biotechnology